Clinical trial Recruiting at 5 sites Interventional Ages 18 and up

Comparing two endoscopic techniques for detecting cancer in ulcerative colitis patients

Official title: Endoscopic Screening for Dysplasia in Patients With Longstanding Ulcerative Colitis: Classical Chromo-endoscopy Versus NBI , FICE and EPK-i.

Run by Universitaire Ziekenhuizen KU Leuven · NCT01882205 · Data updated 2026-11-12

This study is testing if two different endoscopy techniques can better find cancer in people with long-term ulcerative colitis while reducing the need for random biopsies.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment402 (estimated)
SponsorUniversitaire Ziekenhuizen KU Leuven
Academic / other
Locations5 sites (Leuven and 4 other locations)
StatusRecruiting
StartedMay 2008
Main results expectedDecember 2018
Study endsNovember 2027
Registry record updatedJuly 10, 2024
Trial IDNCT01882205 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients with longstanding ulcerative colitis who have been diagnosed for at least 8 years.

Probably not a fit

Patients with active ulcerative colitis or a personal history of colorectal cancer may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effectiveness of chromoendoscopy and virtual chromoendoscopy techniques in detecting neoplasia in patients with longstanding ulcerative colitis. Patients enrolled in this study will undergo surveillance endoscopies to evaluate the performance of these imaging methods against the current standard of care, which involves random biopsies. The study seeks to determine if chromoendoscopy, which uses contrast agents, can reduce the number of biopsies needed while improving the detection of cancerous lesions. The findings could lead to more efficient and cost-effective surveillance protocols for patients at risk of colon cancer due to ulcerative colitis.

Why it matters

Potential benefit: If successful, this study could lead to improved cancer detection rates and reduced need for unnecessary biopsies in patients with ulcerative colitis.

How similar studies have gone: Previous studies have shown that chromoendoscopy can enhance dysplasia detection, suggesting that this approach may be effective, though the specific comparison with virtual chromoendoscopy is less established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with longstanding ulcerative colitis ( 8 years after diagnosis or pancolitis and 10 years after diagnosis of left-sided colitis)
* Signed informed consent form
* Previous surveillance endoscopy \> 1 year

Exclusion Criteria:

* Active ulcerative colitis, \> 20 cm from the margo ani
* Personal history of colorectal cancer
* Allergy or intolerance to methylene blue
* Refusing or incapable to agree with informed consent
* Age younger than 18 years
* Pregnant women

Where it's running

  • University Hospitals Leuven
    Leuven, Belgium
    Recruiting
  • H.-Hartziekenhuis Roeselare-Menen VZW
    Roeselaere, Belgium
    Recruiting
  • McGill University Health Center
    Montreal, Canada
    Recruiting
  • Copenhagen University Hospital Herlev
    Copenhagen, Denmark
    Recruiting
  • Academic Medical center Maastricht
    Maastricht, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.